Vibalogics increases its single-use bioreactor and purification capacity with a new manufacturing line to meet demand for oncolytic virus and viral vector manufacturing services.
ABL Europe will provide development, manufacturing and quality control release testing services for SillaJen’s oncolytic virus candidate JX-970 at its facility in Strasbourg.
Vector-based vaccine tech firm Vaccitech has secured £20m ($27.1m) in venture capital with investors Google Ventures, Sequoia China, Neptune Ventures and Oxford Sciences Innovation.
VirionHealth Ltd is poised to start Phase I trials of new biological antivirals - called defective interfering particles - after receiving £13m ($15m) from private equity group Abingworth.
Novasep has signed a €4.7m ($5.4m) agreement with Celladon, a clinical-stage biotechnology company, to prepare to supply the drug substance for the heart failure treatment Mydicar.
Applied Genetic Technologies Corporation (AGTC), a developer of biologics for rare eye diseases, has agreed to let SAFC to manufacture gene therapies for clients using its HAVE platform.
The draft guidance aims to provide sponsors of virus or bacteria-based gene therapy products (VBGT products) and oncolytic viruses or bacteria (oncolytic products) with recommendations on how to conduct shedding studies during preclinical and clinical...
